The results showed that 10.9% of patients in the Absorb arm showed higher rates of target lesion failure (a composite of heart-related death, heart attack related to the treated vessel and revascularization), compared with 7.9% for the Xience cohort.
The rate of heart attack was also higher for the Absorb contingent, at 7.3% compared with 4.9% for Xience.
The FDA said it’s investigating the higher adverse event rate for Absorb, which it approved in July 2016 with the proviso that Abbott run a 5-year post-market study of the device.
But I’ll be the first to admit, we don’t know for sure whether or not this device will do better over the long haul.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.